Former Kite execs Arie Belldegrun and David Chang splashed back onto the scene last month with a new startup, an array of off-the-shelf CAR-T assets and $300 million to bankroll it all. Now, Stat reports, Belldegrun is looking to sign on Cowen analyst Eri
Teva said in its first-quarter earnings report that it expects an FDA pre-approval inspection in the coming months of the plant where its partner Celltrion produces the API for Teva's migraine treatment fremanezumab.
Wall Street speculation had focused